5^th Annual Conference on Hematologists November 07-08, 2022 Madrid, Spain

Track 1: Various Aspects of Hematology

All aspects of pediatric hematology and oncology are referred to as pediatric hematology. It focuses on pathology, immunology, and pharmacology in the context of pediatric cancer and hematological illnesses. Hematologists are doctors who specialise in hematological illnesses. Hematologists at certain hospitals are also in charge of the laboratory. Hematology laboratories are managed and managed by pathologists who specialise in the diagnosis of hematological diseases, known as hematopathologists.

• Clinical Hematology and Hematopathology
• Experimental Hematology and Ethical Issues
• Scope of Animal Hematology and Its Importance
• Hematology practice and Case Reports

Track 2: Hematologic Oncology

Hematology, sometimes known as oncology, is a branch of medicine that focuses on the diagnosis, treatment, and prevention of illnesses of the blood. Oncology is the study of cancer. Cancer is defined as unregulated cell proliferation and invasion of other tissues. Because of mutations in their DNA or the accumulation of abnormalities, cells can become malignant. Anemia persists in cancer patients and its incidence rises while the patient undergoes chemotherapy. Cancer induces the production of inflammatory cytokines, which stop erythropoiesis and erythropoietin (EPO) synthesis. Because EPO decreases plasma volume and activates the production of inflammatory cytokines separately of enhancing erythropoiesis, increased erythropoiesis stimulating medicines dose may also effect poor survivals.

• Anemia
• Cancer metastasis
• Hypercalcemia
• Hematologist – Oncologist

Track 3:  Hematology Nursing

Patients with hematological diseases and cancer are treated by a hematology nurse. Hematology nursing is comparable to oncology nursing, and hematology nurses work with doctors, hematologists, and other nurses. Third-level knowledge and specific abilities are required in this speciality. Regardless of whether a hematology nurse focuses on adults or children, many will be dealing with incurable or life-threatening disorders such as hemophilia, sickle cell anemia, leukaemia, and lymphoma.

• Research patient treatments
• Prescribe medication
• Operate and monitor medical equipment
• Request lab work

Track 4: Blood Disease Condition and Treatment

A physician will undertake a physical exam, examine family medical history, conduct a review of individual and family medical history, and perform blood tests, biopsy, and bone marrow aspiration if anemia is not obvious. Depending on the specific diagnosis, treatment may include chemotherapy to destroy abnormal cells, immunotherapy to control the immune system's ability to fight disease, transfusions to replace disease-causing blood cells, gene therapy to replace a disease-causing gene, and blood-component therapies for bleeding disorders like hemophilia.

• Bleeding and clotting disorders
• Anticoagulation
• Hematological malignancy
• Acute leukaemia

Track 5:  Hematology and Stem Cell Research

Advances in hematopoietic stem cell immunology and histocompatibility have an impact on HSC transplantation breakthroughs. Immunotherapy is an important part of the HSC transplant process. In a number of ways, HSC transplantation is connected to cancer immunotherapy. Hematologists who investigate HSCs have become pioneers in the field of induced pluripotent stem cells, which is still in its infancy (iPS). Using the iPS cell fields' reprogramming principles, T cells are now being reprogrammed to generate memory stem cells. Hematology, cancer, stem cell biology, and immunology have all been merged to change the definition of a hematologist.

• Allogeneic stem cell transplant
• Autologous stem cell transplant
• Blood forming stem cell transplant

Track 6:  Blood Transplantation, Thrombosis and Hemostasis

A blood transfusion is a frequent medical operation in which donated blood is injected into a vein and administered to the recipient. It is a life-saving technique that assists in the restoration of blood loss caused by surgery or injury. These frequently happen in the absence of any barriers. When issues do occur, they are usually minor. A thrombus is the end result of the blood coagulation process, which is also known as a blood clot. The two components of thrombus are red blood cells and aggregated platelets, which combine to produce a cross-linked fibrin protein. The creation of a blood clot within a blood vessel is known as thrombosis. It prevents blood from flowing freely through the circulatory system. Hemostasis is a clotting-control mechanism. The first stage of wound healing is referred to as this.

• Acute & delayed transfusion reactions
• A restrictive transfusion strategy
• Noninfectious serious hazards of transfusion

Track 7: New Drug Development in Hematology

The procedure of bringing new therapeutic medicines for the treatment of damage into the commercial centre is a time-consuming and expensive one. When everything is said and done, the most recent techniques for tranquillize disclosure are selected. Medication repurposing asserts the ability to quickly introduce fresh restorative strategies into clinical trials with minimal effort. By employing their known toxicological, pharmacology, and pharmacokinetics, identified on-patent or off-patent drugs with undiscovered anticancer movement can be quickly first in class into clinical testing for this unique indicator. Pedantic assembling can take a look at the medicine confession sector in this way, and smaller biotechnology companies can "de-risk" early-stage placid declaration projects. Some inferential techniques for identifying sedate repurposing opportunities are highlighted in this article, with a focus on hematopoietic malignancies.

• Ruxolitinib
• Acalabrutinib
• Givosiran
• Hematologic malignancies

Track 9: Hematology and Pharma Industry

The entire market for the hematological pharmaceuticals in peak point as it is as frequent as applicable anticipate to be upgraded over two or three decades. According to all over the market master, curing of hematological disorders and definite market is relayed upon to construct at the rate of 8.5% from 2015-2022. The most recent drugs to invade the hematology market are recombinant erythropoietin products G-CSF and granulocyte-macrophage colony stimulating factor at the year of 1989. These have recognized the treatment of cancer and other serious diseases like AIDS. Recombinant drugs are currently influence the blood cell stimulant sector, and are a foremost area for pharmaceutical companies.

Track 10: Hematological Disorders

Hematologic diseases are defined as changes in the immune system, blood cells, or proteins that affect blood clotting. Laboratory testing to diagnose blood problems normally begin with a simple blood draw from a vein using a needle and syringe. Further analysis may require investigation of the bone marrow, which is where blood cells form. The complete blood count (CBC) is the most frequent blood test, which examines all cellular components such as red blood cells, white blood cells, and platelets. Anemia is a condition in which the blood has a low amount of red blood cells. Pale complexion, shortness of breath with exercise, and exhaustion are all symptoms of severe anemia.

• Acute lymphoblastic leukemia
• Acute myeloid leukemia
• Deep vein thrombosis
• Hemochromatosis
• Hodgkin's lymphoma

Track 11: Blood Based Products

Blood is a national resource that is obtained via voluntary public donations and processed into medications in order to improve the health of that same population. Blood is a unique biological in that the "raw material" is the blood donor, and the donor's health is closely tied to the health of the recipient. Medicines are classified as essential in the List of Essential Medicines (EML) based on their safety and efficacy, availability, convenience of use in different contexts, comparative cost-effectiveness, and public health Blood Products. Blood products are made up of blood and blood components produced as single-donor outcomes for direct transfusion, such as red blood cells, platelets, and plasma, as well as a variety of plasma-derived pharmaceutical products.

• Plasma
• Heparin & Warfarin
• Cryopecipitation

Track 12: Pediatric Hematology

The availability of the science of hematology, which developed microscopy for exhibiting blood cell morphology, made pediatric hematology a specialisation possible. It was necessary to illustrate the usual blood values of infancy and childhood before pediatric blood disorders could be explained. Many of the early research focused on the specific characteristics of neonatal blood. Following the confirmation of standard values, specific blood diseases and hematologic problems in children began to be documented in Europe and the United States. Pediatric hematology oncology is a broad and multidisciplinary field that encompasses abnormalities of established precursors in the bone marrow and their blood components, as well as coagulation and fibrinolytic systems in the plasma.

• Hemophoitic system
• Pluripotent stem cells
• Hematologic values
• Organization of globin genes
• Clinical approach to a child with Anemia